Gastric Cancer

Janjigian Reviews the Evolving Role of Anti-HER2 Agents in Advanced Gastric Cancer

October 05, 2020

In an interview with Targeted Oncology following a virtual presentation for the ISGIO 2020, Yelena Janjigian, MD, provided an overview of the role of HER2-targeted therapies in advanced gastric cancer. She also explained the importance of biomarker testing in this space.

FDA Grants Fast Track Designation to DKN-01 in Gastric/GEJ Adenocarcinoma

September 24, 2020

The FDA has granted a Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express the protein DKK1, following disease progression on or after prior treatment with fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, human epidermal receptor growth factor/neu-targeted therapy.

Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers

September 21, 2020

In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.

Nivolumab/Ipilimumab Improves Survival Outcomes in Metastatic Gastric/GEJ Cancers

August 11, 2020

Overall survival and progression-free survival were improved with nivolumab plus ipilimumab and chemotherapy compared with chemotherapy alone as frontline treatment of patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer

July 16, 2020

Yu Sunakawa, MD, PhD, discusses the data observed in the DELIVER trial, which was presented as an updated analysis of nivolumab in patients with advanced gastric cancer at the European Society of Oncology World Congress on Gastrointestinal Cancer 2020.